Compare AKR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | ADMA |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 1996 | 2012 |
| Metric | AKR | ADMA |
|---|---|---|
| Price | $21.94 | $7.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $22.25 | ★ $25.67 |
| AVG Volume (30 Days) | 844.4K | ★ 5.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | 0.19 |
| Revenue | ★ $410,757,000.00 | $42,219,783.00 |
| Revenue This Year | $3.21 | $27.46 |
| Revenue Next Year | $12.17 | $22.11 |
| P/E Ratio | $98.64 | ★ $41.58 |
| Revenue Growth | 14.20 | ★ 43.85 |
| 52 Week Low | $18.04 | $7.21 |
| 52 Week High | $22.50 | $22.37 |
| Indicator | AKR | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 27.46 |
| Support Level | $19.61 | $7.34 |
| Resistance Level | $22.32 | $16.61 |
| Average True Range (ATR) | 0.36 | 0.29 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 67.49 | 5.60 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: REIT Portfolio segment consists of high-quality retail properties located in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds the retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.